450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition

Abstract

Mitogen-activated protein kinase (MAPK) pathway inhibition activates Unc-51–like autophagy activated kinase (ULK) 1/2 and initiates autophagy to promote survival of RAS/RAF mutant cancers. DCC-3116, a first-in-class potent and selective ULK inhibitor, demonstrated preclinical antitumour activity in combination with MAPK pathway inhibitors. Here, we describe initial DCC-3116 monotherapy results from an ongoing phase I study.